Phototherapy and Exchange Transfusion
Phototherapy and exchange transfusion are the two principal interventions for lowering bilirubin in neonatal hyperbilirubinemia. Phototherapy uses visible light to convert bilirubin into water-soluble forms that can be excreted without conjugation; exchange transfusion physically removes bilirubin and antibody-coated red cells and is reserved for severe or rapidly rising hyperbilirubinemia.
Definition
Phototherapy is the therapeutic application of visible light, typically in the blue-green spectrum, to convert unconjugated bilirubin in the skin into water-soluble photoproducts that can be excreted in bile and urine without hepatic conjugation. Exchange transfusion is a procedure in which the newborn's blood is removed in small aliquots and replaced with donor blood, directly removing bilirubin, antibody, and sensitized red cells.
Scope
This entry covers the physical and physiologic basis of phototherapy (photoisomerization and structural conversion of bilirubin) and of exchange transfusion, the relationship of each to disease severity, and their place in the management of hyperbilirubinemia. It explains how these modalities work as reference knowledge; it does not provide irradiance settings, treatment thresholds, or procedural instructions.
Core questions
- How does light lower bilirubin without requiring hepatic conjugation?
- What determines the effectiveness of phototherapy?
- When is exchange transfusion used rather than phototherapy alone?
- What does exchange transfusion accomplish that phototherapy cannot?
Key concepts
- Bilirubin photoisomerization
- Structural isomerization (lumirubin formation)
- Photo-oxidation
- Spectrum and irradiance (dose) of light
- Total-body surface area exposed
- Exchange transfusion
- Double-volume exchange
- Intensive versus conventional phototherapy
Mechanisms
Phototherapy works by delivering light absorbed by bilirubin in the skin, which drives photochemical reactions: reversible configurational isomerization and irreversible structural isomerization to lumirubin, plus a smaller contribution from photo-oxidation. These photoproducts are more water-soluble than native bilirubin and can be excreted in bile and urine without first being conjugated by the liver, bypassing the rate-limiting step that is immature in newborns. Effectiveness depends chiefly on the wavelength (blue-green light overlapping bilirubin's absorption peak is most effective), the irradiance delivered, and the body-surface area exposed. Exchange transfusion, by contrast, mechanically removes bilirubin from the circulation along with maternal antibody and antibody-coated red cells, and is therefore particularly relevant in severe hemolytic disease; it acts rapidly but is more invasive and is reserved for the most severe or refractory hyperbilirubinemia.
Clinical relevance
Understanding how phototherapy and exchange transfusion lower bilirubin clarifies why phototherapy is the first-line, noninvasive intervention and why exchange transfusion is held in reserve for severe disease. This entry presents the mechanisms and evidence for reference; the decision to initiate either modality, and the thresholds that govern it, are clinical judgements defined by current guidelines and are not provided here.
Epidemiology
Phototherapy is among the most commonly administered treatments in newborn care, while exchange transfusion has become uncommon where effective phototherapy and antenatal prophylaxis for hemolytic disease are available, being reserved for the most severe cases. The thresholds at which each is considered depend on gestational age, postnatal age, and neurotoxicity risk factors.
Evidence & guidelines
The review by Maisels and McDonagh describes the photochemistry and clinical use of phototherapy, and American Academy of Pediatrics guidelines (2004; revised 2022) define gestational-age- and risk-based thresholds for phototherapy and exchange transfusion in infants of 35 or more weeks' gestation. These thresholds and the technical specifications for effective phototherapy belong to those sources and are not reproduced here.
History
The bilirubin-lowering effect of light was recognized in the 1950s after observations that sunlight and blue light reduced jaundice in a hospital nursery, leading to the introduction of clinical phototherapy. Exchange transfusion had earlier been developed to treat severe hemolytic disease of the newborn. Over subsequent decades the photochemical basis of phototherapy was clarified, technology and light sources improved, and the relative roles of the two modalities shifted as prevention and effective phototherapy reduced the need for exchange transfusion.
Debates
- What are the benefits and possible harms of intensive phototherapy?
- More intensive phototherapy lowers bilirubin faster, but questions have been raised about possible adverse effects, especially in extremely preterm infants, prompting attention to using phototherapy at appropriate thresholds rather than indiscriminately.
Key figures
- M. Jeffrey Maisels
- Antony F. McDonagh
- R. J. Cremer
- Jerold Lucey
Related topics
Seminal works
- maisels-2008
- aap-2004
- kemper-2022
Frequently asked questions
- How does phototherapy lower bilirubin?
- Light absorbed by bilirubin in the skin converts it into more water-soluble photoproducts, chiefly through structural isomerization to lumirubin, which can be excreted in bile and urine without needing the liver to conjugate it first.
- When is exchange transfusion needed instead of phototherapy?
- Exchange transfusion is reserved for severe or rapidly rising hyperbilirubinemia, often in hemolytic disease, because it physically removes bilirubin and antibody-coated red cells, whereas phototherapy alone may be insufficient in the most severe cases.